ReviewMedical mycology2018
Triazole resistance surveillance in Aspergillus fumigatus.
Review in Medical mycology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- Antifungal Susceptibility andMicroorganisms · 2026Article
- Laboratory Diagnostics of Aspergillosis: Present State and Future Directions.Journal of fungi (Basel, Switzerland) · 2026Review
- Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026Review
- Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.Medical mycology · 2025Article
- Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Loss of theMicrobiology spectrum · 2025Article
- Appearance of Environment-Linked Azole Resistance in the Aspergillus fumigatus Complex in New Zealand.Mycoses · 2025Article
- Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Climate Change Impacts on Environmental Fungi: Human Health and Fungal Disease.Current topics in microbiology and immunology · 2025Review
- Distribution and Epidemiological Characteristics of Clinical Isolates ofInfection and drug resistance · 2025Article
- Understanding the clinical and environmental drivers of antifungal resistance in the One Health context.Microbiology (Reading, England) · 2024Review
- Detection of pan-azole resistant Aspergillus fumigatus in horticulture and a composting facility in Belgium.Medical mycology · 2024Article
- Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches.Journal of fungi (Basel, Switzerland) · 2024Review
- Azole Resistance in Veterinary Clinical Aspergillus fumigatus Isolates in the Netherlands.Mycopathologia · 2024Article
- Azole resistance mechanisms and population structure of the human pathogenApplied and environmental microbiology · 2024Article
- What do We Know about Cryptic Aspergillosis?Microorganisms · 2024Review
- Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom.Eye (London, England) · 2024Article
- Progress in the application of nanoparticles for the treatment of fungal infections: A review.Mycology · 2024Review
- Emerging Antifungal Resistance in Fungal Pathogens.Current clinical microbiology reports · 2024Review
- Ibrexafungerp: A narrative overview.Current research in microbial sciences · 2024Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Triazole resistance is an increasing concern in the opportunistic mold Aspergillus fumigatus. Resistance can develop through exposure to azole compounds during azole therapy or in the environment. Resistance mutations are commonly found in the Cyp51A-gene, although other known and unknown resistance mechanisms may be present. Surveillance studies show triazole resistance in six continents, although the presence of resistance remains unknown in many countries. In most countries, resistance mutations associated with the environment dominate, but it remains unclear if these resistance traits predominately migrate or arise locally. Patients with triazole-resistant aspergillus disease may fail to antifungal therapy, but only a limited number of cohort studies have been performed that show conflicting results. Treatment failure might be due to diagnostic delay or due to the limited number of alternative treatment options. The ISHAM/ECMM Aspergillus Resistance Surveillance working group was set up to facilitate surveillance studies and stimulate international collaborations. Important aims are to determine the resistance epidemiology in countries where this information is currently lacking, to gain more insight in the clinical implications of triazole resistance through a registry and to unify nomenclature through consensus definitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.